Redeye maintains a positive stance on Dynavox following another standout quarter. In Q2, organic growth reached an impressive 37%, with broad-based momentum across geographies, product categories, and a growing uptake among younger autism users. Despite elevated non-recurring costs, underlying profitability remains solid. We have raised our estimates and valuation to reflect the continued outperformance and sustained growth trajectory.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/